1.2) Ligandrol - LGD 4033 - LEAN MUSCLE GAINS

ENHANCEMENTS

  • LEAN MUSCLE MASS GAINER

  • INCREASED STRENGTH LEVELS

  • INCREASED SKELETAL MUSCLE DENSITY

  • PREVENTS MUSCLE WASTING

  • ANABOLIC MUSCLE GROWTH

  • DECREASES FAT STORES

 

BEST FOR:

  1. Rapid hard muscle gains and strength increases.
  2. If you are wanting to put on muscular mass, or have trouble putting on size.
  3. Muscular hypertrophy.
  4. Increase muscular density without holding water.

 

SUMMARY:

 

Specific enhancements include substantial muscle growth and strength increases due to the anabolic qualities of the modulator in the muscle.

LGD-4033 has parallel effects to anabolic steroids without the negative side effects that come from using. When used correctly, LGD-4033 has rapid muscle growth benefits and provides the user with noticeable muscular strength and definition due to the efficiency of how the compound targets the receptors within the muscles themselves.

Clinical runs also showed that LGD 4033 has the ability to set off the following benefits when taken consistently: an increase in strength levels, lean muscle mass, a drop in body fat, it also has healing properties and does not cause the undesirable side effects caused by prohormones and anabolic steroids.  

Further benefits include:

- Nutrient absorption efficiency.

- Anabolic muscular response to resistance training.

- Increased muscular density growth.

- Slow muscle catabolism process (low muscle wastage).

 

LABORATORY INGREDIENTS:

A: 4-((R)-2-((R)-2,2,2-trifluoro-1-hydroxyethyl)pyrrolidin-1-yl)-2-trifluoroMethyl)benzonitrile.

B: Propylene glycol. 

 

RECOMMENDED DOSAGE:

A: 10mg / mL @ 30 mL. 1mL per day.

 

INSTRUCTIONS FOR DOSAGE:

A:  Take ONE full squeeze of liquid up to the 1mL mark in the dropper. Empty contents orally with meals. 

B:  Users also have the option of adding the liquid into shakes, meals and other drinks.

 

These products are not for use in preventing, curing, or treating a particular disease or ailments.

FOR RESEARCH PURPOSES

Subscribe